Curosurf

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This medication helps improve lung function and oxygenation, supporting critical care for newborns.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs are not fully developed and lack sufficient surfactant, a substance that keeps the air sacs open. By administering Curosurf, healthcare providers aim to replace the missing surfactant, facilitating easier breathing and improving oxygen levels in the blood. The medication is administered directly into the lungs via endotracheal tube, making it suitable for use in neonatal intensive care units.

Curosurf works by coating the inner surface of the lungs, reducing surface tension and preventing the collapse of alveoli. This action helps to improve lung compliance and gas exchange, allowing for better oxygenation and reduced respiratory effort. The effects of Curosurf are typically observed soon after administration, providing immediate support to infants experiencing respiratory distress.

Curosurf should be used under the supervision of healthcare professionals experienced in neonatal care. It is essential to follow proper administration techniques to minimize the risk of complications. Patients with a history of severe allergic reactions to porcine-derived products should exercise caution, as Curosurf is derived from porcine lung tissue. Regular monitoring of the infant's respiratory status and oxygen levels is recommended during and after administration.

Curosurf is generally well-tolerated, but interactions with other medications should be considered. It is important to inform healthcare providers about any other medications or treatments the infant is receiving. While specific drug interactions are not well-documented, caution is advised when using Curosurf in conjunction with other respiratory therapies or medications that may affect lung function.